Risedronate Sodium Delayed-release Tablets, 35 mg, Once-a-Week, 1 tablet per blister (NDC 0093-5509-19), packaged in 4 blisters per carton (NDC 0093-5509-44), Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454.
Published March 15, 2017 · Recall initiated: February 17, 2017
Summary
FDA records drug Class III recall D-0511-2017, published March 15, 2017 and initiated February 17, 2017. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Reported quantity: 25,916 cartons; Lot: Lot # 34025762A, Exp 06/17. Class III means the product is not likely to cause adverse health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Failed Dissolution Specifications: low out of specification dissolution results found during stability testing.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Teva Pharmaceuticals USA
- Distributor
- Nationwide in the United States and Puerto Rico
- Lot
- Lot # 34025762A, Exp 06/17
- Risk classification
- Class III
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAMimvey (estradiol and norethindrone acetate tablets USP), 1 mg/0.5 mg, packaged in cartons of 28 Tablets, RxFebruary 9, 2022
- FDADoxylamine Succinate and Pyridoxine Hydrochloride Delayed-Release Tablets 10 mg/10 mg, 100-count bottle, RxFebruary 9, 2022
- FDAMimvey (estradiol and norethindrone acetate tablets USP) 1 mg/0.5 mg, packaged in cartons of 28 Tablets, RxFebruary 9, 2022
- FDATretinoin Capsules, 10 mg, 100 count bottle, Rx Only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454,February 9, 2022
- FDACalcipotriene Cream 0.0005%, packaged in a) 60g tube, (NDC 66993-877-61), b) 120g tube (NDC 66993-877-78), RxMarch 15, 2017
- FDAEdex (alprostadil for injection) 10mcg, packaged in a 2 pack carton, Rx only, Manufactured in Germany for:March 15, 2017
Questions about this recall
Was Risedronate Sodium Delayed-release Tablets, 35 mg, Once-a-Week, 1 tablet per blister (NDC 0093-5509-19), packaged in 4 blisters per carton (NDC 0093-5509-44), Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454. recalled?
Yes. FDA published recall D-0511-2017 on March 15, 2017. Reported hazard: Failed Dissolution Specifications: low out of specification dissolution results found during stability testing.
What should I do if I have this product?
Voluntary: Firm initiated · Letter